- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07642466
Adult Bladder and Quality of Life Evaluation in Spina Bifida (ABLE-SB)
10 juni 2026 uppdaterad av: Blayne Welk
Patient Reported Outcomes for Bladder Management Strategies in Young Adults With Spina Bifida
Spina bifida (SB) is a birth defect that affects the spine, often causing paralysis in the legs and problems with bladder and bowel control.
Managing these bladder issues is important, but different methods, like using a catheter or surgery, can impact a person's quality of life.
This study looks at how different bladder management methods affect the quality of life for young people with SB.
Researchers will ask people with SB to complete a survey about how they manage their bladder and how it impacts their daily lives.
The main goal is to find out if certain bladder management methods are associated with a better quality of life.
This information could help doctors make better treatment decisions and counsel young people living with SB.
Studieöversikt
Status
Rekrytering
Betingelser
Detaljerad beskrivning
Spina bifida is a congenital defect of the spine where some of the spinal cord and its covering (meninges) are exposed through a gap in the lower back or sacrum; this often results in paralysis of the lower limbs.
The majority of spina bifida (SB) patients also have pelvic floor dysfunction (bladder, bowel, prolapse, sexual function) because of neurologic damage to this portion of the spinal nerves, and this increases the risk of their long-term morbidity.
These problems place a substantial burden on patients' physical health and quality of life (QoL).
Serious urological complications, such as urosepsis, skin breakdown, and renal failure, can occur in this patient population due to bladder dysfunction.
Approximately 50% of young adults with SB have renal dysfunction, 50% have urinary incontinence, and they are nine times more likely to present with urinary tract infections.
The "gold standard" bladder management strategy when a person with SB is unable to void spontaneously is to perform clean intermittent catheterization (CIC).
Alternatives to CIC include spontaneous voiding (if possible), incontinence products, an indwelling catheter (IDC), or reconstructive surgery (to create a urinary diversion or to enable CIC).
However, IDC and surgery have increased risks of specific complications, including the risk of bladder cancer, urethral damage, urinary infections, and surgical morbidity.
People with SB usually discuss bladder management options with their urologist, however they may prioritize a variety of factors around bladder management that directly affect their QOL, and these may not be as apparent to urologists.
This is further complicated when patients reach adolescence and young adulthood; at this age they transition from pediatric to adult care providers, all while transitioning in other areas of their life (such as increasing responsibility, cognitive growth, and a wish for more independence).
These factors may all impact thoughts about bladder management.
Few studies have addressed QoL in relation to different bladder/bowel management methods in this SB age group, and most have not considered things like health literacy and cognitive function.
Studietyp
Observationell
Inskrivning (Beräknad)
300
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Mary McKibbon, BNSc
- Telefonnummer: 519-646-6367
- E-post: mary.mckibbon@sjhc.london.on.ca
Studieorter
-
-
Ontario
-
London, Ontario, Kanada
- Rekrytering
- St Joseph's Hospital
-
Kontakt:
- Mary McKibbon, BNSc
- Telefonnummer: 5196466367
- E-post: mary.mckibbon@sjhc.london.on.ca
-
Kontakt:
- Brenda Hodgins
- Telefonnummer: 5196466000
- E-post: brenda.hodgins@sjhc.london.on.ca
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Testmetod
Icke-sannolikhetsprov
Studera befolkning
To be included in the study, participants have to be adolescents (13-17 years of age) or adults (≥18 years of age) with SB and no acute health changes.
SB included all types, including SB occulta, meningocele, lipomeningocele, and myelomeningocele.
The investigators are interested in including the SB transitional age group as well, recognizing this age group represents unique and diverse psychosocial, cognitive and functional abilities.
Beskrivning
Inclusion Criteria:
- Diagnosis of SB
- Age ≥13 years of age
- Able to effectively communicate in English or Spanish
- Willing to provide informed consent for participation and answer a set of questionnaires
Exclusion Criteria:
- Reconstructive surgery or urinary diversion in the last 3 months
- Hospital admission in the last 1 month
- Inconsistent or newly changed (within the last month) method of bladder management
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Voiding/incontinence
SB patients who manage their bladder with voiding/incontinence
|
|
CIC
SB patients who manage their bladder with clean intermittent catheters
|
|
Diversion
SB patients who manage their urination with a surgical bladder diversion
|
|
Indwelling catheter
SB patients who manage their bladder with an indwelling catheter
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
QUAlity of Life Assessment in Spina bifida (bladder and bowel quality of life domain)
Tidsram: At the time of enrollment
|
The QUALAS is a validated quality of life measure for teens and adults with spina bifida.
It is scored from 0-100, with a higher score meaning better QOL
|
At the time of enrollment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Neurogenic Bladder Symptom Score-Short Form
Tidsram: At time of enrollment
|
The NBSS-SF is a validated assessment of bladder symptom burden
|
At time of enrollment
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Blayne Welk, MD MSc, Western University
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
1 januari 2025
Primärt slutförande (Beräknad)
31 oktober 2026
Avslutad studie (Beräknad)
1 november 2026
Studieregistreringsdatum
Först inskickad
4 juni 2026
Först inskickad som uppfyllde QC-kriterierna
4 juni 2026
Första postat (Faktisk)
11 juni 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
12 juni 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
10 juni 2026
Senast verifierad
1 juni 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 15140 (City of Hope Medical Center)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
OBESLUTSAM
IPD-planbeskrivning
The investigators will consider sharing data on a case by case basis, after the primary analysis is complete.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .